Oxford Immunotec Global PLC
DelistedCIK 1586049fmd_02V48S4WHB4T8TZXCFKZM1PBB5Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2020, 32 periods
Latest annual · FY2019
Millions- Total revenues
- 74
- Gross profit
- 54
- Operating income
- (6)
- Net income
- (2)
- Free cash flow
- (9)
Latest quarter · Q3 FY2020
Millions- Total revenues
- 19
- Gross profit
- 15
- Operating income
- 0
- Net income
- (0)
- Free cash flow
- (5)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2016 to FY2019
- +16.2%
- Revenue, 5 yearsFY2014 to FY2019
- +8.3%
- Net income, 5 yearsFY2014 to FY2019
- n/m
Oxford Immunotec Global PLC financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2019 | FY2018 | Change | Source |
|---|---|---|---|---|
| Revenue | $73.7 million | $59.8 million | +23.4% | 10-K 2020-03-06 · proof |
| Gross profit | $54.4 million | $42.9 million | +26.8% | 10-K 2020-03-06 · proof |
| Operating income | -$6.1 million | -$20.7 million | 10-K 2020-03-06 · proof | |
| Net income | -$1.8 million | $120.8 million | -101.5% | 10-K 2020-03-06 · proof |
| Cash from operating activities | -$7.2 million | -$32.1 million | 10-K 2020-03-06 · proof | |
| Free cash flow | -$8.8 million | -$37.5 million | 10-K 2020-03-06 · proof | |
| Total assets | $235.3 million | $232.1 million | +1.3% | 10-K 2020-03-06 · proof |
| Total liabilities | $21.6 million | $18.1 million | +19% | 10-K 2020-03-06 · proof |
| Cash and cash equivalents | $181.3 million | $192.8 million | -6% | 10-K 2020-03-06 · proof |
- What was Oxford Immunotec Global PLC's revenue in fiscal 2019?
- Oxford Immunotec Global PLC reported revenue of $73.7 million for fiscal 2019 (the year ended Dec 31, 2019), against $59.8 million the year before (+23.4%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What was Oxford Immunotec Global PLC's gross profit in fiscal 2019?
- Oxford Immunotec Global PLC reported gross profit of $54.4 million for fiscal 2019 (the year ended Dec 31, 2019), against $42.9 million the year before (+26.8%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What was Oxford Immunotec Global PLC's operating income in fiscal 2019?
- Oxford Immunotec Global PLC reported operating income of -$6.1 million for fiscal 2019 (the year ended Dec 31, 2019), against -$20.7 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What was Oxford Immunotec Global PLC's net income in fiscal 2019?
- Oxford Immunotec Global PLC reported net income of -$1.8 million for fiscal 2019 (the year ended Dec 31, 2019), against $120.8 million the year before (-101.5%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What was Oxford Immunotec Global PLC's cash from operating activities in fiscal 2019?
- Oxford Immunotec Global PLC reported cash from operating activities of -$7.2 million for fiscal 2019 (the year ended Dec 31, 2019), against -$32.1 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What was Oxford Immunotec Global PLC's free cash flow in fiscal 2019?
- Oxford Immunotec Global PLC reported free cash flow of -$8.8 million for fiscal 2019 (the year ended Dec 31, 2019), against -$37.5 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What are Oxford Immunotec Global PLC's total assets?
- As of Dec 31, 2019, Oxford Immunotec Global PLC reported total assets of $235.3 million, against $232.1 million a year earlier (+1.3%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What are Oxford Immunotec Global PLC's total liabilities?
- As of Dec 31, 2019, Oxford Immunotec Global PLC reported total liabilities of $21.6 million, against $18.1 million a year earlier (+19%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
- What are Oxford Immunotec Global PLC's cash and cash equivalents?
- As of Dec 31, 2019, Oxford Immunotec Global PLC reported cash and cash equivalents of $181.3 million, against $192.8 million a year earlier (-6%). Source: the 10-K filed with the SEC on Mar 6, 2020. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1586049&period_type=annual&limit=5"Information only, not investment advice.